This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Neurology				
Schizophrenia	Phosphodiesterase-10A (PDE-10A)	<p><i>In vitro</i> and rat studies identified a class of PDE-10A inhibitors that could help treat schizophrenia. SAR studies identified imidazo[1,5-<i>a</i>]pyrido[3,2-<i>e</i>]pyrazine derivatives that potently inhibited PDE-10A, a known schizophrenia target. In a rat model of schizophrenia, the best inhibitors prevented schizophrenia-related hyperactivity and abnormal movements with efficacy comparable to that of the antipsychotic clozapine. Next steps include clinical testing of the compounds.</p> <p>Novartis AG markets Clozaril clozapine to treat schizophrenia.</p> <p>Azur Pharma Ltd. markets FazaClo clozapine to treat schizophrenia.</p> <p>SciBX 3(20); doi:10.1038/scibx.2010.628 Published online May 20, 2010</p>	<p>Patent application filed worldwide for CNS diseases; licensed by Pfizer Inc. for all indications; unavailable for licensing; Biotie Therapies Corp. looking for additional collaboration partners in the field</p>	<p>Hofgen, N. <i>et al.</i> <i>J. Med. Chem.</i>; published online May 7, 2010; doi:10.1021/jm1002793</p> <p>Contact: Norbert Höfgen, Biotie Therapies Corp., Radebeul, Germany e-mail: norbert.hofgen@biotie.com</p>